Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications.
Fiche publication
Date publication
février 2024
Journal
Breast cancer research : BCR
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEVY Jérôme, Pr MERROUCHE Yacine, Dr POTTEAUX Stéphane, Pr BENSUSSAN Armand
Tous les auteurs :
Scheffges C, Devy J, Giustiniani J, Francois S, Cartier L, Merrouche Y, Foussat A, Potteaux S, Bensussan A, Marie-Cardine A
Lien Pubmed
Résumé
Despite major therapeutic advances, triple-negative breast cancer (TNBC) still presents a worth prognosis than hormone receptors-positive breast cancers. One major issue relies in the molecular and mutational heterogeneity of TNBC subtypes that is reinforced by the absence of reliable tumor-antigen that could serve as a specific target to further promote efficient tumor cell recognition and depletion. CD160 is a receptor mainly expressed by NK lymphocytes and presenting two isoforms, namely the GPI-anchored form (CD160-GPI) and the transmembrane isoform (CD160-TM). While CD160-GPI is constitutively expressed on resting cells and involved in the generation of NK cells' cytotoxic activity, CD160-TM is neo-synthesized upon activation and promotes the amplification of NK cells' killing ability.
Mots clés
Antibody-based therapy, CD160-TM, TNBC, Tumor antigen
Référence
Breast Cancer Res. 2024 02 15;26(1):28